Prognostic Impact of Fusobacterium nucleatum Depends on Combined Tumor Location and Microsatellite Instability Status in Stage II/III Colorectal Cancers Treated with Adjuvant Chemotherapy

다국어 초록 (Multilingual Abstract)

Background: This study aimed to investigate the prognostic impact of intratumoral Fusobacterium nucleatum in colorectal cancer (CRC) treated with adjuvant chemotherapy. Methods: F. nucleatum DNA was quantitatively measured in a total of 593 CRC tissues retrospectively collected from surgically resected specimens of stage III or high-risk stage II CRC patients who had received curative surgery and subsequent oxaliplatin-based adjuvant chemotherapy (either FOLFOX or CAPOX). Each case was classified into one of the three categories: F. nucleatum–high, –low, or –negative. Results: No significant differences in survival were observed between the F. nucleatum–high and –low/negative groups in the 593 CRCs (p = .671). Subgroup analyses according to tumor location demonstrated that disease-free survival was significantly better in F. nucleatum–high than in –low/negative patients with non-sigmoid colon cancer (including cecal, ascending, transverse, and descending colon cancers; n = 219; log-rank p = .026). In multivariate analysis, F. nucleatum was determined to be an independent prognostic factor in non-sigmoid colon cancers (hazard ratio, 0.42; 95% confidence interval, 0.18 to 0.97; p = .043). Furthermore, the favorable prognostic effect of F. nucleatum–high was observed only in a non-microsatellite instability- high (non-MSI-high) subset of non-sigmoid colon cancers (log-rank p = 0.014), but not in a MSI-high subset (log-rank p = 0.844), suggesting that the combined status of tumor location and MSI may be a critical factor for different prognostic impacts of F. nucleatum in CRCs treated with adjuvant chemotherapy. Conclusions: Intratumoral F. nucleatum load is a potential prognostic factor in a non-MSI-high/non-sigmoid/non-rectal cancer subset of stage II/III CRCs treated with oxaliplatin-based adjuvant chemotherapy.

참고문헌 (Reference)

1 Stintzing S, "Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes" 84 : 69-80, 2017

2 Geller LT, "Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine" 357 : 1156-1160, 2017

3 Bae JM, "Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway" 140 : 406-412, 2016

4 Kim JH, "Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer" 20 : 4230-4243, 2014

5 Dejea CM, "Microbiota organization is a distinct feature of proximal colorectal cancers" 111 : 18321-18326, 2014

6 Yu J, "Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway" 139 : 1318-1326, 2016

7 Park HE, "Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma" 471 : 329-336, 2017

8 Pagès F, "International validation of the consensus Immunoscore for the classification of colon cancer : a prognostic and accuracy study" 391 : 2128-2139, 2018

9 Gopalakrishnan V, "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients" 359 : 97-103, 2018

10 Routy B, "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors" 359 : 91-97, 2018

11 Kostic AD, "Genomic analysis identifies association of Fusobacterium with colorectal carcinoma" 22 : 292-298, 2012

12 Rubinstein MR, "Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin" 14 : 195-206, 2013

13 Yu T, "Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy" 170 : 548.e16-563.e16, 2017

14 Kostic AD, "Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumorimmune microenvironment" 14 : 207-215, 2013

15 Castellarin M, "Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma" 22 : 299-306, 2012

16 Mima K, "Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis" 65 : 1973-1980, 2016

17 Mima K, "Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location" 7 : e200-, 2016

18 Hamada T, "Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status" 6 : 1327-1336, 2018

19 Flanagan L, "Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome" 33 : 1381-1390, 2014

20 Yamaoka Y, "Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population" 53 : 517-524, 2018

21 Shang FM, "Fusobacterium nucleatum and colorectal cancer : a review" 10 : 71-81, 2018

22 Mima K, "Fusobacterium nucleatum and T cells in colorectal carcinoma" 1 : 653-661, 2015

23 Tahara T, "Fusobacterium in colonic flora and molecular features of colorectal carcinoma" 74 : 1311-1318, 2014

24 Abed J, "Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumorexpressed Gal-GalNAc" 20 : 215-225, 2016

25 Bae JM, "Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma" 30 : 267-277, 2017

26 Ito M, "Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway" 137 : 1258-1268, 2015

27 Lee DW, "Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer" 25 : 3389-3395, 2018

28 Vetizou M, "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota" 350 : 1079-1084, 2015

29 Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer" 58 : 5248-5257, 1998